MYOSLID: A Critical Modulator of Cancer Hallmarks
Genes · 2025
DOI: 10.3390/genes16030341 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2025. Verfasst von Kanupriya Medhi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Non-Coding RNA and Cancer Biology Lab, Department of Zoology, Central University of Punjab, Ghudda, Bathinda 151401, Punjab, India. Hauptthemen laut MEDLINE: Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite being the leading cause of death worldwide, cancer still lacks precise biomarkers for effective targeting, limiting efforts to reduce mortality rates. This review explores the role and clinical significance of a newly identified long non-coding RNA, MYOSLID, in cancer progression. MYOSLID has emerged as a critical modulator in cancer progression by influencing key hallmarks such as proliferation, immune evasion, metastasis, and metabolic reprogramming. It promotes tumor cell growth by stabilizing hypoxia-inducible factor 1 and acting as a competing endogenous RNA (ceRNA) to sequester tumor-suppressive microRNAs like miR-29c-3p, thereby enhancing oncogene expression. It facilitates immune evasion by upregulating PD-L1, suppressing T cell activation, and modulating necroptosis pathways involving RIPK1 and RIPK3. Additionally, MYOSLID drives metastasis by regulating epithelial–mesenchymal transition markers such as LAMB3 and Slug while promoting RAB13-mediated cytoskeletal remodeling and enhancing cancer cell invasion. We have obtained the expression of MYOSLID from TCGA and the ENCORI database. The expression of colorectal adenocarcinoma (COAD) and head and neck squamous cell carcinoma (HNSCC) is associated with poor prognosis and lower survival rate. Given its significant potential as a diagnostic biomarker and therapeutic target, further research is required to elucidate its precise molecular mechanisms and therapeutic applications in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Non-Coding RNA and Cancer Biology Lab, Department of Zoology, Central University of Punjab, Ghudda, Bathinda 151401, Punjab, India.
- 3rd Floor, Jyoti Pinnacle Building, Survey No.11, Kondapur Village, Serilingampally Mandal, Ranga Reddy District, Hyderabad 500081, Telangana, India.
- Department of Translational Medicine, Clinical Research Centre, Skåne University Hospital, Lund University, 20213 Malmö, Sweden.
- Department of Bio-Sciences and Technology, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala 133207, India.
ORCID-Profile: Vivek Uttam, Vikas Yadav, Hardeep Singh Tuli, Aklank Jain
Zitieren
APA
Medhi, K., Mukherjee, S., Dagar, A., Tiwari, A. K., Daffara, S., Bana, S., Uttam, V., Ansari, M. R., Yadav, V., Tuli, H. S., & Jain, A. (2025). MYOSLID: A Critical Modulator of Cancer Hallmarks. Genes. https://doi.org/10.3390/genes16030341
Vancouver
Medhi K, Mukherjee S, Dagar A, Tiwari AK, Daffara S, Bana S, et al. MYOSLID: A Critical Modulator of Cancer Hallmarks. Genes. 2025. doi:10.3390/genes16030341
BibTeX
@article{Medhi2025,
author = {Medhi, Kanupriya and Mukherjee, Sagarika and Dagar, Aastha and Tiwari, Ashutosh Kumar and Daffara, Sia and Bana, Sanjana and Uttam, Vivek and Ansari, Md Rizwan and Yadav, Vikas and Tuli, Hardeep Singh and Jain, Aklank},
title = {MYOSLID: A Critical Modulator of Cancer Hallmarks},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16030341}
}
EUVIMED